<DOC>
	<DOCNO>NCT00415571</DOCNO>
	<brief_summary>The objective study ass compare preliminary efficacy , safety tolerability fispemifene 300 mg placebo give daily 8 week treatment hypogonadal men erectile dysfunction ( ED ) unresponsive PDE5 inhibitor .</brief_summary>
	<brief_title>Efficacy Safety Evaluating Fispemifene Treatment Hypogonadal Men With Erectile Dysfunction Unresponsive PDE5 Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Hypogonadal ( morning total testosterone level ≤400 ng/dl ) men age ≥20 ED unresponsive PDE5 inhibitor , demonstrate International Index Erectile Function ( IIEF ) result 28day lead period .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Erectile Dysfunction</keyword>
</DOC>